A Make Medicines Affordable partner, the Initiative for Medicines, Access and Knowledge (I-MAK), has published a special edition ‘Roadmap report’ on dolutegravir. The report provides current clinical, cost, and patent information in order to inform strategies to expand currently limited access to Dolutegravir. One of the recommendations is to pursue a coordinated compulsory license strategy, especially in countries in which patent barriers are unlikely to be removed because of lower patentability standards.
Publisher: I-MAK. Year: 2017